Drug Chief at FDA accused of Conflict

The Wall Street Journal reports the apparent conflict of interest allegagion against Janet Woodcock, Director of FDA's Center for Drug Evaluation, because of a scientific paper she co-authored with a prohibited source--allegations include providing that party special access, even where there was a recusal in place.  Perception is everything.  See full article at  http://online.wsj.com/article/SB125003545637224263.html